Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Breast Cancer

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 60 articles: HTML format

Single Articles

August 2023
1. ZHANG X, Guo H, Chen J, Xu C, et al
   Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
   Cancer Lett. 2023 Aug 17:216355. doi: 10.1016/j.canlet.2023.216355.
   PubMed     Abstract available
   
   
   July 2023
2. CREMER J, Brohee L, Dupont L, Lefevre C, et al
   Acidosis-induced regulation of adipocyte G0S2 promotes crosstalk between adipocytes and breast cancer cells as well as tumor progression.
   Cancer Lett. 2023;569:216306.
   PubMed     Abstract available
   
   
   
3. TER STEEGE EJ, Doornbos LW, Haughton PD, van Diest PJ, et al
   R-spondin-3 promotes proliferation and invasion of breast cancer cells independently of Wnt signaling.
   Cancer Lett. 2023 Jul 3:216301. doi: 10.1016/j.canlet.2023.216301.
   PubMed     Abstract available
   
   
   May 2023
4. REN Z, Xue Y, Liu L, Zhang X, et al
   Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function.
   Cancer Lett. 2023 May 14:216221. doi: 10.1016/j.canlet.2023.216221.
   PubMed     Abstract available
   
   
   
5. ZHANG Y, Chen J, Mi D, Ling J, et al
   Corrigendum to "Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFbeta signaling pathway" [Canc. Lett. (2023) 216142].
   Cancer Lett. 2023 May 6:216195. doi: 10.1016/j.canlet.2023.216195.
   PubMed    
   
   
   March 2023
6. ZHANG Y, Chen J, Mi D, Ling J, et al
   Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFbeta signaling pathway.
   Cancer Lett. 2023;560:216142.
   PubMed     Abstract available
   
   
   
7. DENG L, Liao L, Zhang YL, Hu SY, et al
   MYC-driven U2SURP regulates alternative splicing of SAT1 to promote triple-negative breast cancer progression.
   Cancer Lett. 2023 Mar 10:216124. doi: 10.1016/j.canlet.2023.216124.
   PubMed     Abstract available
   
   
   
8. MA J, Zhu J, Li J, Liu J, et al
   Enhanced E6AP-mediated ubiquitination of ENO1 via LINC00663 contributes to radiosensitivity of breast cancer by regulating mitochondrial homeostasis.
   Cancer Lett. 2023 Mar 3:216118. doi: 10.1016/j.canlet.2023.216118.
   PubMed     Abstract available
   
   
   February 2023
9. BERG AL, Showalter MR, Kosaisawe N, Hu M, et al
   Cellular transformation promotes the incorporation of docosahexaenoic acid into the endolysosome-specific lipid bis(monoacylglycerol)phosphate in breast cancer.
   Cancer Lett. 2023;557:216090.
   PubMed     Abstract available
   
   
   
10. GANDULLO-SANCHEZ L, Pandiella A
    An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs.
    Cancer Lett. 2023;554:216024.
    PubMed     Abstract available
    
    
    January 2023
11. WANG L, Mi D, Hu J, Liu W, et al
    A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer.
    Cancer Lett. 2023;555:216049.
    PubMed     Abstract available
    
    
    December 2022
12. BERNARDO G, Le Noci V, Ottaviano E, De Cecco L, et al
    Reduction of Staphylococcus epidermidis in the mammary tumor microbiota induces antitumor immunity and decreases breast cancer aggressiveness.
    Cancer Lett. 2022;555:216041.
    PubMed     Abstract available
    
    
    
13. LEE Y, Graham P, Li Y
    Extracellular vesicles as a novel approach for breast cancer therapeutics.
    Cancer Lett. 2022 Dec 12:216036. doi: 10.1016/j.canlet.2022.216036.
    PubMed     Abstract available
    
    
    October 2022
14. XIE XF, Wu NQ, Wu JF, Zhang GL, et al
    CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
    Cancer Lett. 2022 Oct 6:215944. doi: 10.1016/j.canlet.2022.215944.
    PubMed     Abstract available
    
    
    
15. LUO Y, Tang W, Xiang S, Feng J, et al
    Non-coding RNAs in breast cancer: Implications for programmed cell death.
    Cancer Lett. 2022 Oct 3:215929. doi: 10.1016/j.canlet.2022.215929.
    PubMed     Abstract available
    
    
    
16. HUANG CP, Liu LC, Chang CC, Wu CC, et al
    Intratumoral xenogeneic tissue-specific cell immunotherapy inhibits tumor growth by increasing antitumor immunity in murine triple negative breast and pancreatic tumor models.
    Cancer Lett. 2022;545:115478.
    PubMed     Abstract available
    
    
    September 2022
17. WANG M, Wei R, Li G, Bi HL, et al
    Corrigendum to "SUMOylation of SYNJ2BP-COX16 promotes breast cancer progression through DRP1-mediated mitochondrial fission" [Canc. Lett. 547 (2022) 215871].
    Cancer Lett. 2022;549:215923.
    PubMed    
    
    
    
18. LUO M, Li J, Yang Q, Xu S, et al
    N4BP3 promotes breast cancer metastasis via NEDD4-mediated E-cadherin ubiquitination and degradation.
    Cancer Lett. 2022 Sep 23:215926. doi: 10.1016/j.canlet.2022.215926.
    PubMed     Abstract available
    
    
    
19. LI T, Zhai D, Zhang M, Ye R, et al
    KIF17 maintains the epithelial phenotype of breast cancer cells and curbs tumour metastasis.
    Cancer Lett. 2022 Sep 8:215904. doi: 10.1016/j.canlet.2022.215904.
    PubMed     Abstract available
    
    
    
20. LIU X, Zhang G, Yu T, He J, et al
    Exosomes deliver lncRNA DARS-AS1 siRNA to inhibit chronic unpredictable mild stress-induced TNBC metastasis.
    Cancer Lett. 2022;543:215781.
    PubMed     Abstract available
    
    
    August 2022
21. ZHANG T, Huang P
    Response to letter to the editor regarding "Hsp90 inhibitor-loaded IR780 micelles for mitochondria-targeted mild-temperature photothermal therapy in xenograft models of human breast cancer".
    Cancer Lett. 2022 Aug 23:215881. doi: 10.1016/j.canlet.2022.215881.
    PubMed    
    
    
    
22. WANG M, Wei R, Li G, Bi HL, et al
    SUMOylation of SYNJ2BP-COX16 promotes breast cancer progression through DRP1-mediated mitochondrial fission.
    Cancer Lett. 2022 Aug 20:215871. doi: 10.1016/j.canlet.2022.215871.
    PubMed     Abstract available
    
    
    
23. BAHREYNI A, Liu H, Mohamud Y, Xue YC, et al
    A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice.
    Cancer Lett. 2022 Aug 19:215849. doi: 10.1016/j.canlet.2022.215849.
    PubMed     Abstract available
    
    
    
24. WANG Y, Zhou X, Lei Y, Chu Y, et al
    NNMT contributes to high metastasis of triple negative breast cancer by enhancing PP2A/MEK/ERK/c-Jun/ABCA1 pathway mediated membrane fluidity.
    Cancer Lett. 2022;547:215884.
    PubMed     Abstract available
    
    
    
25. ZHOU L, Li H, Sun T, Wen X, et al
    HULC targets the IGF1R-PI3K-AKT axis in trans to promote breast cancer metastasis and cisplatin resistance.
    Cancer Lett. 2022 Aug 15:215861. doi: 10.1016/j.canlet.2022.215861.
    PubMed     Abstract available
    
    
    
26. LIANG Y, Zhou X, Xie Q, Sun H, et al
    CD146 interaction with integrin beta1 activates LATS1-YAP signaling and induces radiation-resistance in breast cancer cells.
    Cancer Lett. 2022;546:215856.
    PubMed     Abstract available
    
    
    July 2022
27. RODRIGUES-FERREIRA S, Nahmias C
    Predictive biomarkers for personalized medicine in breast cancer.
    Cancer Lett. 2022;545:215828.
    PubMed     Abstract available
    
    
    
28. PERDRIX ROSELL A, Maiques O, Martin JAJ, Chakravarty P, et al
    Early functional mismatch between breast cancer cells and their tumour microenvironment suppresses long term growth.
    Cancer Lett. 2022 Jul 5:215800. doi: 10.1016/j.canlet.2022.215800.
    PubMed     Abstract available
    
    
    June 2022
29. ZHAI D, Zhang M, Li Y, Bi J, et al
    LINC01194 recruits NUMA1 to promote ubiquitination of RYR2 to enhance malignant progression in triple-negative breast cancer.
    Cancer Lett. 2022 Jun 21:215797. doi: 10.1016/j.canlet.2022.215797.
    PubMed     Abstract available
    
    
    
30. MEHLICH D, Marusiak AA
    Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Cancer Lett. 2022 Jun 3:215775. doi: 10.1016/j.canlet.2022.215775.
    PubMed     Abstract available
    
    
    May 2022
31. YUE P, Zhu Y, Brotherton-Pleiss C, Fu W, et al
    Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo.
    Cancer Lett. 2022;534:215613.
    PubMed     Abstract available
    
    
    
32. LAW ME, Yaaghubi E, Ghilardi AF, Davis BJ, et al
    Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death.
    Cancer Lett. 2022;534:215604.
    PubMed     Abstract available
    
    
    
33. GOBEL A, Riffel RM, Hofbauer LC, Rachner TD, et al
    The mevalonate pathway in breast cancer biology.
    Cancer Lett. 2022 May 28:215761. doi: 10.1016/j.canlet.2022.215761.
    PubMed     Abstract available
    
    
    
34. SIRKISOON SR, Wong GL, Aguayo NR, Doheny DL, et al
    Breast cancer extracellular vesicles-derived miR-1290 activates astrocytes in the brain metastatic microenvironment via the FOXA2-->CNTF axis to promote progression of brain metastases.
    Cancer Lett. 2022 May 16:215726. doi: 10.1016/j.canlet.2022.215726.
    PubMed     Abstract available
    
    
    
35. TIMILSINA S, Rajamanickam S, Rao AD, Subbarayalu P, et al
    The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events.
    Cancer Lett. 2022 May 11:215717. doi: 10.1016/j.canlet.2022.215717.
    PubMed     Abstract available
    
    
    
36. LIU Y, Zhang Z, Gao X, Ma Q, et al
    Corrigendum to "Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B" [Canc. Lett. 535 (2022) 215629].
    Cancer Lett. 2022 May 5:215701. doi: 10.1016/j.canlet.2022.215701.
    PubMed    
    
    
    April 2022
37. MA S, Zhang J, Guo Q, Cao C, et al
    Disrupting PHF8-TOPBP1 connection elicits a breast tumor-specific vulnerability to chemotherapeutics.
    Cancer Lett. 2022;530:29-44.
    PubMed     Abstract available
    
    
    March 2022
38. YU S, Li W, Tang L, Fan X, et al
    Depression in breast cancer patients: Immunopathogenesis and immunotherapy.
    Cancer Lett. 2022;536:215648.
    PubMed     Abstract available
    
    
    
39. LIU Y, Zhang Z, Gao X, Ma Q, et al
    Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B.
    Cancer Lett. 2022 Mar 9:215629. doi: 10.1016/j.canlet.2022.215629.
    PubMed     Abstract available
    
    
    
40. DU G, Sun J, Li Z, Zhang Q, et al
    A feedforward circuit between KLF5 and lncRNA KPRT4 contributes to basal-like breast cancer.
    Cancer Lett. 2022 Mar 5:215618. doi: 10.1016/j.canlet.2022.215618.
    PubMed     Abstract available
    
    
    
41. LYU X, Zhang Q, Fares HM, Wang Y, et al
    Contribution of adipocytes in the tumor microenvironment to breast cancer metabolism.
    Cancer Lett. 2022;534:215616.
    PubMed     Abstract available
    
    
    February 2022
42. SCHREIBER C, Gruber A, Rosswag S, Saraswati S, et al
    Loss of ASAP1 in the MMTV-PyMT model of luminal breast cancer activates AKT, accelerates tumorigenesis, and promotes metastasis.
    Cancer Lett. 2022 Feb 15:215600. doi: 10.1016/j.canlet.2022.215600.
    PubMed     Abstract available
    
    
    January 2022
43. SOTO-GAMEZ A, Wang Y, Zhou X, Seras L, et al
    Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist.
    Cancer Lett. 2022;525:67-75.
    PubMed     Abstract available
    
    
    
44. CHAIB M, Sipe LM, Yarbro JR, Bohm MS, et al
    PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8(+) T cells in breast cancer.
    Cancer Lett. 2022 Jan 21. pii: S0304-3835(22)00025.
    PubMed     Abstract available
    
    
    
45. MISHRA A, Hourigan D, Lindsay AJ
    Inhibition of the endosomal recycling pathway downregulates HER2 activation and overcomes resistance to tyrosine kinase inhibitors in HER2-positive breast cancer.
    Cancer Lett. 2022;529:153-167.
    PubMed     Abstract available
    
    
    
46. PENG Y, Chen Z, He Y, Li P, et al
    Non-muscle myosin II isoforms orchestrate substrate stiffness sensing to promote cancer cell contractility and migration.
    Cancer Lett. 2022;524:245-258.
    PubMed     Abstract available
    
    
    
47. ZOU Y, Liu B, Li L, Yin Q, et al
    IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors.
    Cancer Lett. 2022;524:121-130.
    PubMed     Abstract available
    
    
    December 2021
48. WANG Z, Wang F, Ding XY, Li TE, et al
    Hippo/YAP signaling choreographs the tumor immune microenvironment to promote triple negative breast cancer progression via TAZ/IL-34 axis.
    Cancer Lett. 2021 Dec 17. pii: S0304-3835(21)00632.
    PubMed     Abstract available
    
    
    
49. CHAI C, Wu HH, Abuetabh Y, Sergi C, et al
    Regulation of the tumor suppressor PTEN in triple-negative breast cancer.
    Cancer Lett. 2021;527:41-48.
    PubMed     Abstract available
    
    
    
50. TANG W, Xia M, Liao Y, Fang Y, et al
    Exosomes in triple negative breast cancer: From bench to bedside.
    Cancer Lett. 2021;527:1-9.
    PubMed     Abstract available
    
    
    November 2021
51. CHADELLE L, Liu J, Choesmel-Cadamuro V, Karginov AV, et al
    PKCtheta-mediated serine/threonine phosphorylations of FAK govern adhesion and protrusion dynamics within the lamellipodia of migrating breast cancer cells.
    Cancer Lett. 2021 Nov 23. pii: S0304-3835(21)00599.
    PubMed     Abstract available
    
    
    
52. KHUMUKCHAM SS, Penugurti V, Soni A, Uppala V, et al
    A reciprocal feedback loop between HIF-1alpha and HPIP controls phenotypic plasticity in breast cancer cells.
    Cancer Lett. 2021 Nov 9. pii: S0304-3835(21)00568.
    PubMed     Abstract available
    
    
    
53. ALRAOUJI NN, Hendrayani SF, Ghebeh H, Al-Mohanna FH, et al
    Osteoprotegerin (OPG) mediates the anti-carcinogenic effects of normal breast fibroblasts and targets cancer stem cells through inhibition of the beta-catenin pathway.
    Cancer Lett. 2021;520:374-384.
    PubMed     Abstract available
    
    
    
54. LEE O, Bosland MC, Wang M, Shidfar A, et al
    Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
    Cancer Lett. 2021;520:255-266.
    PubMed     Abstract available
    
    
    October 2021
55. WANG SF, Chang YL, Tony Tzeng YD, Wu CL, et al
    Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS/calcium up-regulated amphiregulin-estrogen receptor loop signaling.
    Cancer Lett. 2021 Oct 2. pii: S0304-3835(21)00504.
    PubMed     Abstract available
    
    
    
56. ALSHEIKH HAM, Metge BJ, Ha CM, Hinshaw DC, et al
    Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding.
    Cancer Lett. 2021;517:24-34.
    PubMed     Abstract available
    
    
    September 2021
57. XIA M, Zu X, Chen Z, Wen G, et al
    Noncoding RNAs in triple negative breast cancer: Mechanisms for chemoresistance.
    Cancer Lett. 2021 Sep 30. pii: S0304-3835(21)00499.
    PubMed     Abstract available
    
    
    
58. LI C, Qiu S, Jin K, Zheng X, et al
    Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression.
    Cancer Lett. 2021;523:43-56.
    PubMed     Abstract available
    
    
    
59. YADAV P, Sharma P, Sundaram S, Venkatraman G, et al
    SLC7A11/ xCT is a target of miR-5096 and its restoration partially rescues miR-5096-mediated ferroptosis and anti-tumor effects in human breast cancer cells.
    Cancer Lett. 2021;522:211-224.
    PubMed     Abstract available
    
    
    June 2021
60. HAN HJ, Sung JY, Kim SH, Yun UJ, et al
    Fibronectin regulates anoikis resistance via cell aggregate formation.
    Cancer Lett. 2021;508:59-72.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: